Company Profile

Cadre Bioscience LLC
Profile last edited on: 8/16/22      CAGE: 8GX25      UEI: HVSVM481KUF9

Business Identifier: Accelerating development of early-stage therapeutics for multiple technology assets.
Year Founded
2020
First Award
2021
Latest Award
2021
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

4330 Duncan Avenue Suite 329
Saint Louis, MO 63110
   (314) 615-6373
   N/A
   www.cadrebioscience.com
Location: Single
Congr. District: 01
County: St. Louis city

Public Profile

A rather unusual company to be receiving SBIR support, Cadre Bioscience are a team of business professionals focused on development of a portfolio of early-stage therapeutic assets. Utilizing an experienced management team, accelerator lab facilities and an extensive network of consultants and collaborators the firm offers what is described as an alternative for innovators wishing to see their technology(ies) that they have developed for the benefit of patients without the need for them to tackle the niceties of founding their own company and raising capital. The Cadre’s experience, infrastructure and network creates greater efficiencies, shortens timelines, and increases chances of success. In their description of the firm, management note that the traditional route of pursuing a commercial path for a therapeutic technology via formation of a start-up company comes with numerous challenges: raising of capital, attracting suitably experienced management and creating a development plan. Often the availability of suitable business and development experience is limited, so that building a company around a single technology during the earliest stages of development is inherently inefficient. By providing a source of this experience and expertise for multiple technologies under the same umbrella, Cadre provides an attractive means for innovators to launch their technology down a path towards commercialization and providing patient benefit. In sum, Cadre Bioscience offers an alternative of their advancing the firm's fledgling therapeutic technology. raising the required venture capital investment needed to rsablish the stand-alone company - that can then fly the Cadre nest with their own dedicated funding, leadership and scientific team

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
15-19
Revenue Range
1.5M-2M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2021 1 NIH $430,855
Project Title: Estrogen-related receptor agonists for the treatment of heart failure
0 1 NIH $353,411
Project Title: Development of a Novel Approach to Immunotherapy.

Key People / Management

  Bob Karr -- Executive Chair and CEO

  Kathleen L Beckmann -- Chief Financial Officer

  Charlie Bolten

  Michael Anthony Tones -- Chief Scientific Officer

Company News

There are no news available.